CTI Clinical Trial and Consulting Services Announces Collaboration with Galectin Therapeutics on Novel Phase I NASH Clinical Trial
CTI Clinical Trial and Consulting Services
(CTI) announces its collaboration with
Galectin Therapeutics
on a first-in-man Phase I clinical trial that will support a proposed indication of GR-MD-02 for treatment of non-alcoholic steatohepatitis (NASH or fatty liver disease) with advanced fibrosis.
The Phase 1 clinical trial is entitled, "A Multi-Center, Partially Blinded, Maximum Tolerated Multiple Dose Escalation, Phase 1 Clinical Trial to Evaluate the Safety of GR-MD-02 in Subjects with Non-Alcoholic Steatohepatitis (NASH) with Advanced Hepatic Fibrosis," and will be conducted in six centers in the United States, all of which have extensive experience in conducting liver disease trials. The trial investigator kick-off meeting was held in Atlanta, GA on April 5, 2013, and it is anticipated that the enrollment and infusion of the first cohort will be completed by the end of Q2 2013.
“CTI is excited to be a part of such a groundbreaking clinical trial that will help a significant and progressive unmet medical need,” according to Lynn Fallon, Executive Vice President and President, Consulting at CTI. “NASH affects between 9 and 15 million people in the United States, and is the third leading indication for liver transplantation. This trial will be critical to helping patients where there is currently no approved medical therapy. CTI has extensive experience in liver disease, fibrosis, and in conducting first-in-human trials.”
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
